Company Overview
Serving patients by providing high quality, affordable and innovative biopharmaceutical products.
Established in 2014, PT Etana Biotechnologies Indonesia (Etana) is an emerging producer of high-quality, affordable and innovative biopharmaceuticals to treat a range of metabolic, autoimmune and other major life-threatening diseases, including cancer.
In order to best serve Indonesian patients, Etana has established a network of strategic alliances and partnerships with international pharmaceutical producers with a strong track record in researching and developing safe and efficacious pharmaceuticals, enabling Etana to offer new treatments to the Indonesian market. At the same time, Etana is working to build Indonesia’s human resources and its own research and production capabilities by establishing environmentally-friendly, multi-purpose biopharmaceutical manufacturing and research facilities, staffed by top graduates from Indonesia’s foremost medical research and educational institutions.
Etana is committed to enabling Indonesians to live long, productive, healthy lives by working proactively with major hospital groups, doctors’ associations, and the national pharmaceutical licensing agency and social health program to ensure that people from all walks of life across the archipelago have access to life-saving and life-enhancing drugs that were previously unavailable or difficult to access in Indonesia. Etana works with the medical establishment to ensure that health care service providers are aware of and capable of deploying the pharmaceuticals it produces to effectively treat patients’ medical conditions.
Indonesians are now living increasingly long lives and demanding higher quality medical care to guard and protect their health. With Indonesia’s expanding prosperity, rising living standards, and the introduction of a universal social health scheme, people’s expectations regarding health and longevity will continue to grow. Etana aims to meet these expanding needs for decades to come by continuing to extend the range and reach of its life-saving biopharmaceutical products, by building and developing the skills of its staff, and by working in close collaboration with all stakeholders involved in improving the health of the nation.